Acadia Pharmaceuticals (ACAD)
Develops NUPLAZID and DAYBUE for neurological and rare diseases.
$20.61
After hours−5.80 (−21.95%)
At close$26.41(+0.04%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 98.60% | 169.89M shares | |
|---|---|---|---|
| 364 holders · as of Jun 30, 2026 | |||
| Insiders | 0.22% | 379.0K shares | |
| 13 holders · as of Aug 7, 2026 | |||
| Other | 1.18% | 2.04M shares | |
| remainder | |||
172.31M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
364 holders · 169.89M shares · 47 new positions · 183 increased · 112 reduced · 41 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 42.91M | 24.91% | +16.2K | Aug 14, 2026 |
| BlackRock, Inc. | 22.52M | 13.07% | +964.3K | Aug 7, 2026 |
| State Street Corp | 9.08M | 5.27% | +743.4K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.84M | 5.13% | +166.8K | Aug 13, 2026 |
| RTW Investments, LP | 7.14M | 4.15% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.76M | 3.35% | +102.4K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 3.69M | 2.14% | +539.8K | Aug 11, 2026 |
| Geode Capital Management, LLC | 3.36M | 1.95% | −106.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Felix J. Bakerincl. FBB3 LLC, Baker Bros. Advisors (GP) LLC +2 more | 25.40% | 43.29M | 13D | Feb 26, 2026 |
| BlackRock, Inc. | 11.90% | 19.88M | 13G | Feb 7, 2025 |
| State Street Corporation | 5.30% | 9.08M | 13G | Aug 7, 2026 |
| Vanguard Portfolio Management | 5.15% | 8.78M | 13G | Apr 28, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 6, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale · 2 lots | 14,292 | $29.22 | 67,828 |
| Aug 5, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 5,849 | $29.00 | 67,828 |
| Jul 30, 2026 | Elizabeth H.Z. Thompsonofficer: EVP, Head of Research & Dev | Sale · 2 lots | 16,558 | $26.13 | 18,994 |
| Jun 26, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 11,421 | $26.08 | 13,088 |
| May 26, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 5,401 | $21.18 | 24,509 |
| May 4, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 3,506 | $21.79 | 66,145 |
| May 4, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 1,332 | $21.79 | 29,129 |
| Apr 7, 2026 | James Kiharaofficer: PRINCIPAL ACCOUNTING OFFICER | Sale | 1,030 | $22.20 | 27,865 |
| Apr 7, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 2,709 | $22.20 | 62,836 |
| Mar 25, 2026 | Mark C. Schneyerofficer: EVP, CHIEF FINANCIAL OFFICER | Sale | 4,177 | $21.47 | 57,299 |
House and Senate disclosures
Not reported.